Press

Why Choose Ibogaine for Healing?: Mindshifting Moments – Stream #2

Jun 21 • 1 min read

Many people use our Neuly psychedelic database and platform to research the many psychedelic compounds that are receiving press and buzz. Of course, there are some that are more popular than others. But what people may overlook, may be the right fit for them. After all, there is a myriad of benefits spanning all available…

Lobe Sciences and Clearway Global Enter into Agreement to Manage Lobe Science’s Global Regulatory and Development Strategy and Implementation

Jun 21 • 3 min read

Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBED), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with Clearway Global LLC. “We are pleased to have the opportunity to team up with the Clearway network and in…

Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics

Jun 20 • 4 min read

Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, has submitted a request with Health Canada for an amendment to its Controlled Substances Dealer’s Licence. The amendment would enable the Company to synthesize, process and distribute pharmaceutical grade…

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Jun 17 • 3 min read

Mydecine Innovations Group (NEO: MYCO | OTC: MYCOF | FSE: 0NFA), a biotechnology aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared MYCO-001 in a recent Investigational New Drug (IND) application, marking the first clearance of the Company’s drug product. The…

Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives

Jun 16 • 3 min read

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it is bolstering its IP with the filing of provisional patent applications to protect data it obtained during its psilocybin preclinical studies and provide protection…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436